



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
WASHINGTON, D.C. 20555-0001

June 13, 1996

The Honorable Roscoe G. Bartlett  
United States House of Representatives  
Washington, D.C. 20515

Dear Congressman Bartlett:

I am responding to your letter dated April 26, 1996, in which you expressed your support for the recent report of the National Academy of Sciences, Institute of Medicine (IOM) entitled, "Radiation in Medicine: A Need for Regulatory Reform." To date, the NRC has received 41 comments on the report, and the staff is continuing to evaluate the responses. Since we have not reached any conclusions on this matter, we are unable to address the questions you raised at this time. If the NRC were to propose to modify the scope of its regulation of the use of byproduct materials for medical purposes, a determination will be made concerning the need for and extent of appropriate legislative proposals and rulemaking. This determination may include a consideration of risk-informed, performance-based regulation. We will provide our views on the questions you raised at a later date.

The Commission appreciates your interest in the NAS report and the regulation of medical uses of radioactive material.

Sincerely,

Shirley Ann Jackson

PDR per Doris Mossburg

4-27-96

270018

9606210246

XA

PDR COMMS NRCC

DF021/1

OVM-6 Commission

x L-4-1, PT 35  
medical use of  
byproduct matl



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
WASHINGTON, D.C. 20555-0001

June 13, 1996

The Honorable Bill Baker  
United States House of Representatives  
Washington, D.C. 20515

Dear Congressman Baker:

I am responding to your letter dated April 26, 1996, in which you expressed your support for the recent report of the National Academy of Sciences, Institute of Medicine (IOM) entitled, "Radiation in Medicine: A Need for Regulatory Reform." To date, the NRC has received 41 comments on the report, and the staff is continuing to evaluate the responses. Since we have not reached any conclusions on this matter, we are unable to address the questions you raised at this time. If the NRC were to propose to modify the scope of its regulation of the use of byproduct materials for medical purposes, a determination will be made concerning the need for and extent of appropriate legislative proposals and rulemaking. This determination may include a consideration of risk-informed, performance-based regulation. We will provide our views on the questions you raised at a later date.

The Commission appreciates your interest in the NAS report and the regulation of medical uses of radioactive material.

Sincerely,

Shirley Ann Jackson



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
WASHINGTON, D.C. 20555-0001

June 13, 1996

The Honorable Dana Rohrabacher  
United States House of Representatives  
Washington, D.C. 20515

Dear Congressman Rohrabacher:

I am responding to your letter dated April 26, 1996, in which you expressed your support for the recent report of the National Academy of Sciences, Institute of Medicine (IOM) entitled, "Radiation in Medicine: A Need for Regulatory Reform." To date, the NRC has received 41 comments on the report, and the staff is continuing to evaluate the responses. Since we have not reached any conclusions on this matter, we are unable to address the questions you raised at this time. If the NRC were to propose to modify the scope of its regulation of the use of byproduct materials for medical purposes, a determination will be made concerning the need for and extent of appropriate legislative proposals and rulemaking. This determination may include a consideration of risk-informed, performance-based regulation. We will provide our views on the questions you raised at a later date.

The Commission appreciates your interest in the NAS report and the regulation of medical uses of radioactive material.

Sincerely,

Shirley Ann Jackson



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
WASHINGTON, D.C. 20555-0001

June 13, 1996

The Honorable Steve Largent  
United States House of Representatives  
Washington, D.C. 20515

Dear Congressman Largent:

I am responding to your letter dated April 26, 1996, in which you expressed your support for the recent report of the National Academy of Sciences, Institute of Medicine (IOM) entitled, "Radiation in Medicine: A Need for Regulatory Reform." To date, the NRC has received 41 comments on the report, and the staff is continuing to evaluate the responses. Since we have not reached any conclusions on this matter, we are unable to address the questions you raised at this time. If the NRC were to propose to modify the scope of its regulation of the use of byproduct materials for medical purposes, a determination will be made concerning the need for and extent of appropriate legislative proposals and rulemaking. This determination may include a consideration of risk-informed, performance-based regulation. We will provide our views on the questions you raised at a later date.

The Commission appreciates your interest in the NAS report and the regulation of medical uses of radioactive material.

Sincerely,

Shirley Ann Jackson



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
WASHINGTON, D.C. 20555-0001

June 13, 1996

The Honorable Vernon J. Ehlers  
United States House of Representatives  
Washington, D.C. 20515

Dear Congressman Ehlers:

I am responding to your letter dated April 26, 1996, in which you expressed your support for the recent report of the National Academy of Sciences, Institute of Medicine (IOM) entitled, "Radiation in Medicine: A Need for Regulatory Reform." To date, the NRC has received 41 comments on the report, and the staff is continuing to evaluate the responses. Since we have not reached any conclusions on this matter, we are unable to address the questions you raised at this time. If the NRC were to propose to modify the scope of its regulation of the use of byproduct materials for medical purposes, a determination will be made concerning the need for and extent of appropriate legislative proposals and rulemaking. This determination may include a consideration of risk-informed, performance-based regulation. We will provide our views on the questions you raised at a later date.

The Commission appreciates your interest in the NAS report and the regulation of medical uses of radioactive material.

Sincerely,

Shirley Ann Jackson



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
WASHINGTON, D.C. 20555-0001

June 13, 1996

The Honorable Matt Salmon  
United States House of Representatives  
Washington, D.C. 20515

Dear Congressman Salmon:

I am responding to your letter dated April 26, 1996, in which you expressed your support for the recent report of the National Academy of Sciences, Institute of Medicine (IOM) entitled, "Radiation in Medicine: A Need for Regulatory Reform." To date, the NRC has received 41 comments on the report, and the staff is continuing to evaluate the responses. Since we have not reached any conclusions on this matter, we are unable to address the questions you raised at this time. If the NRC were to propose to modify the scope of its regulation of the use of byproduct materials for medical purposes, a determination will be made concerning the need for and extent of appropriate legislative proposals and rulemaking. This determination may include a consideration of risk-informed, performance-based regulation. We will provide our views on the questions you raised at a later date.

The Commission appreciates your interest in the NAS report and the regulation of medical uses of radioactive material.

Sincerely,

Shirley Ann Jackson